Evidence map›Paper›PMID 31285425›Full record

ArticleCell death & disease2019

PGRN acts as a novel regulator of mitochondrial homeostasis by facilitating mitophagy and mitochondrial biogenesis to prevent podocyte injury in diabetic nephropathy.

Di Zhou, Meng Zhou, Ziying Wang, Yi Fu, Meng Jia, Xiaojie Wang, Min Liu, Yan Zhang, Yu Sun, Yi Lu and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death & disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 117 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
117citing papers in PubMed, 2 pooled it
10.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

117 citing papers in PubMed, 2 syntheses or guidelines pooled it, 161 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Selective autophagy in kidney health and disease.Nature reviews. Nephrology · 2026
    Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Post‑translational modifications in diabetic kidney disease (Review).International journal of molecular medicine · 2026
    Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

57 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Di ZhouThe Key Laboratory of Infection and Immunity of Shandong Province, Departments of Pharmacology, School of Basic Medical Sciences, Shandong University, Jinan, China.
Meng ZhouThe Key Laboratory of Infection and Immunity of Shandong Province, Departments of Pharmacology, School of Basic Medical Sciences, Shandong University, Jinan, China.
Ziying WangThe Key Laboratory of Infection and Immunity of Shandong Province, Departments of Pharmacology, School of Basic Medical Sciences, Shandong University, Jinan, China.
Yi FuThe Key Laboratory of Infection and Immunity of Shandong Province, Departments of Pharmacology, School of Basic Medical Sciences, Shandong University, Jinan, China.
Meng JiaThe Key Laboratory of Infection and Immunity of Shandong Province, Departments of Pharmacology, School of Basic Medical Sciences, Shandong University, Jinan, China.
Xiaojie WangThe Key Laboratory of Infection and Immunity of Shandong Province, Departments of Pharmacology, School of Basic Medical Sciences, Shandong University, Jinan, China.
Min LiuThe Key Laboratory of Infection and Immunity of Shandong Province, Departments of Pharmacology, School of Basic Medical Sciences, Shandong University, Jinan, China.
Yan ZhangThe Key Laboratory of Infection and Immunity of Shandong Province, Departments of Pharmacology, School of Basic Medical Sciences, Shandong University, Jinan, China.
Yu SunThe Key Laboratory of Infection and Immunity of Shandong Province, Departments of Pharmacology, School of Basic Medical Sciences, Shandong University, Jinan, China.
Yi LuDepartments of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Shandong University, Jinan, China.
Wei TangDepartments of Pathogenic Biology, School of Basic Medical Sciences, Shandong University, Jinan, China. weitang@sdu.edu.cn.ORCID http://orcid.org/0000-0002-4573-3502
Fan YiThe Key Laboratory of Infection and Immunity of Shandong Province, Departments of Pharmacology, School of Basic Medical Sciences, Shandong University, Jinan, China. fanyi@sdu.edu.cn.ORCID http://orcid.org/0000-0001-8634-9788
Shandong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mitochondrial dysfunction is considered as a key mediator in the pathogenesis of diabetic nephropathy (DN). Therapeutic strategies targeting mitochondrial dysfunction hold considerable promise for the treatment of DN. In this study, we investigated the role of progranulin (PGRN), a secreted glycoprotein, in mediating mitochondrial homeostasis and its therapeutic potential in DN. We found that the level of PGRN was significantly reduced in the kidney from STZ-induced diabetic mice and patients with biopsy-proven DN compared with healthy controls. In DN model, PGRN-deficient mice aggravated podocyte injury and proteinuria versus wild-type mice. Functionally, PGRN deficiency exacerbated mitochondrial damage and dysfunction in podocytes from diabetic mice. In vitro, treatment with recombinant human PGRN (rPGRN) attenuated high glucose-induced mitochondrial dysfunction in podocytes accompanied by enhanced mitochondrial biogenesis and mitophagy. Inhibition of mitophagy disturbed the protective effects of PGRN in high glucose-induced podocytotoxicity. Mechanistically, we demonstrated that PGRN maintained mitochondrial homeostasis via PGRN-Sirt1-PGC-1α/FoxO1 signaling-mediated mitochondrial biogenesis and mitophagy. Finally, we provided direct evidence for therapeutic potential of PGRN in mice with DN. This study provides new insights into the novel role of PGRN in maintaining mitochondrial homeostasis, suggesting that PGRN may be an innovative therapeutic strategy for treating patients with DN.

Indexed as

HomeostasisMitophagyOrganelle BiogenesisAcetylationAnimalsBiopsyCell DeathCytoprotectionDiabetes Mellitus, ExperimentalDiabetic NephropathiesForkhead Box Protein O1GlucoseHumansKidneyMice, Inbred C57BLMitochondriaForkhead Box Protein O1Foxo1 protein, mouseGlucosePeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaProgranulinsSirtuin 1

Identifiers

PMID31285425
PMCPMC6614416
OpenAlexW2976176026

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.